Although at least three randomized clinical trials have told us that adjuvant radiation after prostatectomy often affords better results than just taking a “wait-and-see” approach, … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, early, port-surgery, radiation, salvage | Leave a comment »
So the results from the CHAARTED and STAMPEDE trials over the past few years have re-ignited debate over the appropriateness of early use of chemotherapy in the treatment of aggressive forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", aggressive, chemotherapy, early, outcomes | 1 Comment »
So here’s the first important finding that will be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. Data from the UK’s STAMPEDE trial show a significant benefit from combining docetaxel-based chemotherapy with androgen deprivation therapy (ADT) in appropriately selected men. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen, deprivation, docetaxel, early, outcome, STAMPEDE, survival | 17 Comments »
Several studies have tried to address the issue of whether adjuvant radiation actually increases prostate cancer survival in the long term compared to waiting. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, early, post-surgical, radiation, salvage | 4 Comments »
Historically, it has generally been assumed that androgen receptor gene amplification was a result of androgen deprivation therapy (ADT) and occurred in some 20 to 30 percent of men with castration-resistant prostate cancer (CRPC). However, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: amplification, androgen, early, gene, mortality, receptor, risk | 1 Comment »
In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, delayed, deprivation, early, hormone, primary, therapy | Leave a comment »
A new study published on line in the journal Cancer has shown that (a) the cancer-specific survival benefit associated with aggressive treatment for early-stage prostate cancer is reduced with increasing co-morbidity at time of diagnosis, and (b) patients with Charlson scores ≥ 3 gain no survival benefit from aggressive treatment. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: aggressive, Charlson, Co-morbidity, early, mortality, risk, score, Treatment | Leave a comment »
Alas, the latest revisions to the National Comprehensive Cancer Network (NCCN) guidelines on early detection of prostate cancer seem to have instigated more furore than they have clarity (although the original premise behind them may have been well intentioned). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: detection, Diagnosis, early, PSA, risk | 2 Comments »
A international, collaborative research group has but together a new nomogram designed to project outcomes at 5 years after early salvage radiation therapy (eSRT) for men with local disease recurrence after first-line surgery for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: early, nomogram, outcome, prognosis, radiation, salvage | 5 Comments »
The Prostate Cancer Roundtable has endorsed a statement developed by the Prostate Health Education Network (PHEN) on the role of PSA testing in the early detection of prostate cancer among men acknowledged to be at elevated risk. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: "high risk", consensus, detection, early, statement | 36 Comments »
It remains unclear at this time whether the early use of chemotherapy in carefully selected men with intermediate- and high-risk forms of prostate cancer (while the cancer is still believed to be limited in its spread) is associated with superior clinical outcomes compared to other forms of therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: chemohormonal, chemotherapy, early, therapy | 3 Comments »
Many readers may be interested in two expert interviews on the OncologySTAT web site with Dr. Mark Emberton (a member of the Scientific Advisory Board of The “New “Prostate Cancer InfoLink). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: early, focal, stage, therapy | 1 Comment »
A new study from a group at Duke University has attempted to assess whether data based on PSA doubling times in men with PSA levels up to 0.2 ng/ml can be used as effectively to make early treatment decisions for men with a rising PSA after first-line therapy as can PSA doubling times for men with PSA levels higher than 0.2 ng/ml. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: early, PSA doubling time, PSADT, radical prostatectomy, salvage | Leave a comment »
We learned a few other interesting tidbits during a variety of sessions and conversations today. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk, Treatment, Uncategorized | Tagged: abiraterone, bevacizumab, density, early, hormone therapy, late, risk, statin, urologist | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 